Advanced Cell Technology (ACT) is on the product development track, aiming at regenerative medicine for skin by the look of this press release over at Genetic Engineering News: ACT "will provide the human embryonic stem cell-derived skin cells, and Xgene will provide its technology for reconstituting skin from cultured cells, to achieve the mutually beneficial development of advanced in vitro human skin models. The goal of the collaboration is to test the functionality of embryonic skin cells in regenerating skin for numerous applications in medicine. ... The potential of progenitor cells for healing wounds, and restoring lost functionality to patient skin, while minimizing scarring, could be important for the future practice of dermatology."
Link: http://www.genengnews.com/news/bnitem.aspx?name=843719